P S Thomas1, G Heywood. 1. Inflammation Research Unit, School of Pathology, Faculty of Medicine, University of New South Wales, Sydney, Australia. paul.thomas@unsw.edu.au
Abstract
BACKGROUND:Inhaled tumour necrosis factor alpha (TNF alpha) has previously been shown to induce airway neutrophilia and increased airway reactivity in normal subjects. It was hypothesised that a similar challenge would increase airway reactivity in those with mild asthma, but that the inflammatory profile may differ. METHODS:Ten mild asthmatic subjects were recruited on the basis of clinical asthma and either a sensitivity to methacholine within the range defined for asthma or a 20% improvement in forced expiratory volume (FEV(1)) after 200 micro g salbutamol. Subjects inhaled either vehicle control or 60 ng recombinant human (rh)TNF alpha and were studied at baseline, 6, 24, and 48 hours later. Variables included spirometric parameters, methacholine provocative concentration causing a 20% fall in FEV(1) (PC(20)), induced sputum differential cell count, relative sputum level of mRNA of interleukins (IL)-4, IL-5, IL-9, IL-14, IL-15 and TNF alpha, and the exhaled gaseous markers of inflammation, nitric oxide and carbon monoxide. RESULTS:PC(20) showed an increase in sensitivity after TNF alpha compared with control (p<0.01). The mean percentage of neutrophils increased at 24-48 hours (24 hour control: 1.1 (95% CI 0.4 to 2.7) v 9.2 (95% CI 3.5 to 14.9), p<0.05), and there was also a rise in eosinophils (p=0.05). Relative levels of sputum mRNA suggested a rise in expression of TNF alpha, IL-14, and IL-15, but no change in IL-4 and IL-5. Spirometric parameters and exhaled gases showed no significant change. CONCLUSION: The increase in airway responsiveness and sputum inflammatory cell influx in response to rhTNF alpha indicates that TNF alpha may contribute to the airway inflammation that characterises asthma.
RCT Entities:
BACKGROUND: Inhaled tumour necrosis factor alpha (TNF alpha) has previously been shown to induce airway neutrophilia and increased airway reactivity in normal subjects. It was hypothesised that a similar challenge would increase airway reactivity in those with mild asthma, but that the inflammatory profile may differ. METHODS: Ten mild asthmatic subjects were recruited on the basis of clinical asthma and either a sensitivity to methacholine within the range defined for asthma or a 20% improvement in forced expiratory volume (FEV(1)) after 200 micro g salbutamol. Subjects inhaled either vehicle control or 60 ng recombinant human (rh)TNF alpha and were studied at baseline, 6, 24, and 48 hours later. Variables included spirometric parameters, methacholine provocative concentration causing a 20% fall in FEV(1) (PC(20)), induced sputum differential cell count, relative sputum level of mRNA of interleukins (IL)-4, IL-5, IL-9, IL-14, IL-15 and TNF alpha, and the exhaled gaseous markers of inflammation, nitric oxide and carbon monoxide. RESULTS: PC(20) showed an increase in sensitivity after TNF alpha compared with control (p<0.01). The mean percentage of neutrophils increased at 24-48 hours (24 hour control: 1.1 (95% CI 0.4 to 2.7) v 9.2 (95% CI 3.5 to 14.9), p<0.05), and there was also a rise in eosinophils (p=0.05). Relative levels of sputum mRNA suggested a rise in expression of TNF alpha, IL-14, and IL-15, but no change in IL-4 and IL-5. Spirometric parameters and exhaled gases showed no significant change. CONCLUSION: The increase in airway responsiveness and sputum inflammatory cell influx in response to rhTNF alpha indicates that TNF alpha may contribute to the airway inflammation that characterises asthma.
Authors: S Ying; D S Robinson; V Varney; Q Meng; A Tsicopoulos; R Moqbel; S R Durham; A B Kay; Q Hamid Journal: Clin Exp Allergy Date: 1991-11 Impact factor: 5.018
Authors: P Gosset; A Tsicopoulos; B Wallaert; C Vannimenus; M Joseph; A B Tonnel; A Capron Journal: J Allergy Clin Immunol Date: 1991-10 Impact factor: 10.793
Authors: Gregory S Whitehead; Seddon Y Thomas; Karim H Shalaby; Keiko Nakano; Timothy P Moran; James M Ward; Gordon P Flake; Hideki Nakano; Donald N Cook Journal: J Clin Invest Date: 2017-07-31 Impact factor: 14.808
Authors: N Sismanopoulos; D-A Delivanis; D Mavrommati; E Hatziagelaki; P Conti; T C Theoharides Journal: Allergy Date: 2012-10-16 Impact factor: 13.146
Authors: Craig A Friesen; Nancy A Neilan; Jennifer V Schurman; Debra L Taylor; Gregory L Kearns; Susan M Abdel-Rahman Journal: BMC Gastroenterol Date: 2009-05-11 Impact factor: 3.067